Tags

Type your tag names separated by a space and hit enter

Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria.
Mol Genet Metab Rep. 2020 Jun; 23:100575.MG

Abstract

Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq.

Authors+Show Affiliations

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America. Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of America.Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America. Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of America.Department of Human Genetics, Emory University, School of Medicine, Atlanta, GA, United States of America. Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of America.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32181140

Citation

Patrawala, Meera, et al. "Successful Desensitization of Pegvaliase (Palynziq®) in a Patient With Phenylketonuria." Molecular Genetics and Metabolism Reports, vol. 23, 2020, p. 100575.
Patrawala M, Kuruvilla M, Li H. Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. Mol Genet Metab Rep. 2020;23:100575.
Patrawala, M., Kuruvilla, M., & Li, H. (2020). Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. Molecular Genetics and Metabolism Reports, 23, 100575. https://doi.org/10.1016/j.ymgmr.2020.100575
Patrawala M, Kuruvilla M, Li H. Successful Desensitization of Pegvaliase (Palynziq®) in a Patient With Phenylketonuria. Mol Genet Metab Rep. 2020;23:100575. PubMed PMID: 32181140.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. AU - Patrawala,Meera, AU - Kuruvilla,Merin, AU - Li,Hong, Y1 - 2020/03/06/ PY - 2019/11/26/received PY - 2020/02/09/revised PY - 2020/02/10/accepted PY - 2020/3/18/entrez PY - 2020/3/18/pubmed PY - 2020/3/18/medline SP - 100575 EP - 100575 JF - Molecular genetics and metabolism reports JO - Mol Genet Metab Rep VL - 23 N2 - Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq. SN - 2214-4269 UR - https://www.unboundmedicine.com/medline/citation/32181140/Successful_desensitization_of_Pegvaliase_(Palynziq®)_in_a_patient_with_phenylketonuria L2 - https://linkinghub.elsevier.com/retrieve/pii/S2214-4269(20)30021-5 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.